XML 59 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Disaggregation Of Revenue [Line Items]          
Primary sources of revenue, description     We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).    
Revenue recognized     $ 400    
Deferred revenue $ 1,069   $ 1,069   $ 962
Revenue | Minimum | Customer Concentration Risk | Medicare          
Disaggregation Of Revenue [Line Items]          
Concentration risk, percentage 48.00% 28.00% 47.00% 33.00%  
Up Front Cash Payments          
Disaggregation Of Revenue [Line Items]          
Deferred revenue $ 500   $ 500    
Other Long-term Liabilities          
Disaggregation Of Revenue [Line Items]          
Non-current deferred revenue $ 400   $ 400   $ 400